We are live on ! Find out more
XFOR icon

X4 Pharmaceuticals
XFOR

84 hedge funds and large institutions have $388M invested in X4 Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 22 increasing their positions, 23 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

64% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 11

50% more funds holding in top 10

Funds holding in top 10: 4 → 6 (+2)

8% more capital invested

Capital invested by funds: $358M → $388M (+$30.4M)

6% more funds holding

Funds holding: 79 → 84 (+5)

1.01% more ownership

Funds ownership: 102.28% → 103.28% (+1%)

4% less repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 23

Holders
84
Holders Change
+5
Holders Change %
+6.33%
% of All Funds
1.03%
Holding in Top 10
6
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+50%
% of All Funds
0.07%
New
18
Increased
22
Reduced
23
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
DTC
Deep Track Capital
Connecticut
+$4.97M
2
Morgan Stanley
Morgan Stanley
New York
+$4.72M
3
Millennium Management
Millennium Management
New York
+$4.32M
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$3.12M
5
SVCM
Saturn V Capital Management
Texas
+$2.46M

Top Sellers

1
SL
Siren LLC
Connecticut
-$6M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$3.23M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$1.48M
4
SCM
Silverarc Capital Management
Massachusetts
-$1.43M
5
SCM
Stonepine Capital Management
Oregon
-$967K
Name Holding Trade Value Shares
Change 		Change in
Stake
State Street
26
State Street
Massachusetts
$1.67M +$769K +205,300 +104%
Marshall Wace
27
Marshall Wace
United Kingdom
$1.39M +$960K +256,378 +319%
SCM
28
Stonepine Capital Management
Oregon
$1.38M -$967K -258,264 -44%
VA
29
VR Adviser
New York
$1.37M +$1.24M +330,525 New
UBS Group
30
UBS Group
Switzerland
$1.1M +$986K +263,211 +6,375%
ACA
31
Acorn Capital Advisors
New York
$967K -$147K -39,310 -14%
Qube Research & Technologies (QRT)
32
Qube Research & Technologies (QRT)
United Kingdom
$904K +$566K +151,207 +223%
Northern Trust
33
Northern Trust
Illinois
$736K – – –
PFCS
34
Pale Fire Capital SE
Czech Republic
$692K – – –
Bank of America
35
Bank of America
North Carolina
$622K +$430K +114,915 +321%
AAA
36
Affinity Asset Advisors
New York
$599K – – –
PWM
37
Palumbo Wealth Management
New York
$541K +$66.1K +17,657 +16%
BHCM
38
Brevan Howard Capital Management
Jersey
$526K +$477K +127,321 New
SPS
39
Susquehanna Portfolio Strategies
Pennsylvania
$424K +$222K +59,340 +137%
DTL
40
Dynamic Technology Lab
Singapore
$385K +$136K +36,221 New
Charles Schwab
41
Charles Schwab
California
$276K -$146 -39 -0.1%
OAC
42
OMERS Administration Corp
Ontario, Canada
$237K -$194K -51,900 -48%
Hudson Bay Capital Management
43
Hudson Bay Capital Management
Connecticut
$208K +$67.6K +18,048 +56%
CFM
44
Catalyst Funds Management
Australia
$196K +$177K +47,383 New
Jane Street
45
Jane Street
New York
$153K -$203K -54,270 -59%
Citigroup
46
Citigroup
New York
$148K +$12.9K +3,433 +11%
VGA
47
Vanguard Global Advisers
Pennsylvania
$136K +$124K +32,977 New
DC
48
Diametric Capital
Massachusetts
$120K +$109K +28,973 New
Stifel Financial
49
Stifel Financial
Missouri
$90K +$4.84K +1,293 +6%
Invesco
50
Invesco
Georgia
$82.5K +$74.8K +19,968 New
1
2
3 4

XFOR Hedge Fund Activity: Q1 2026 in Review

84 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in X4 Pharmaceuticals (XFOR) for Q1 2026, worth a combined $388M — up 8.5% from $358M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new XFOR positions and 11 closed out — a net gain of 7 holders — while 22 added to existing stakes and 23 trimmed.

The largest buyer was Deep Track Capital, adding an estimated $4.97M. The largest seller was Siren LLC, exiting entirely with an estimated $6M sold.

  • 84 institutional investors held X4 Pharmaceuticals (XFOR) as of Q1 2026, up from 79 in Q4 2025.
  • Funds reported $388M of X4 Pharmaceuticals stock for Q1 2026, up 8.5% quarter-over-quarter.
  • 18 funds opened new X4 Pharmaceuticals positions in Q1 2026 and 11 closed out, a net change of +7 holders.
  • The largest X4 Pharmaceuticals buyer in Q1 2026 was Deep Track Capital, an estimated $4.97M added.
  • The largest X4 Pharmaceuticals seller in Q1 2026 was Siren LLC, an estimated $6M sold.

Based on aggregated 13F filings for Q1 2026.